RAF-MEK-ERK pathway in cancer evolution and treatment

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works

On the origin of cancer cells

Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · see citing works

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

Cell Signaling by Receptor Tyrosine Kinases

Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929 · see citing works

mTOR Signaling in Growth, Metabolism, and Disease

Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555 · see citing works

ras oncogenes in human cancer: a review.

Bos, J. L. (1989) · PubMed · Cited by 5,061 · see citing works

AMPK: guardian of metabolism and mitochondrial homeostasis

Herzig, S., & Shaw, R. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.95 · Cited by 4,094 · see citing works

Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*

Pearson, G. W., Robinson, F. L., Gibson, T. B., Xu, B.-E., Karandikar, M. S., Berman, K. S., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,044 · see citing works

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,019 · see citing works

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works

HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia

Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · see citing works

The MAPK signaling cascade

Seger, R., & Krebs, E. G. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.9.7601337 · Cited by 3,631 · see citing works

PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo

Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,396 · see citing works

MYC on the Path to Cancer

Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390 · see citing works

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works

Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase

Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Dyk, D. E. V., Pitts, W. J., Earl, R. A., Hobbs, F. W., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,016 · see citing works

MAPK signal pathways in the regulation of cell proliferation in mammalian cells

ZHANG, W., & LIU, H. T. (2002) · Cell Research · doi:10.1038/sj.cr.7290105 · Cited by 2,845 · see citing works

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,800 · see citing works

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · see citing works

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,198 · see citing works

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111 · see citing works

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043 · see citing works

Cell adhesion: integrating cytoskeletal dynamics and cellular tension

Parsons, J. T., Horwitz, A. R., & Schwartz, M. A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2957 · Cited by 1,991 · see citing works

RAS Proteins and Their Regulators in Human Disease

Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · see citing works

Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms

Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., & Greenberg, M. E. (1999) · Science · doi:10.1126/science.286.5443.1358 · Cited by 1,887 · see citing works

ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF

Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radzlejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., & Yancopoulos, G. D. (1991) · Cell · doi:10.1016/0092-8674(91)90098-j · Cited by 1,876 · see citing works

Mitogen-activated protein kinases in innate immunity

Arthur, J. S. C., & Ley, S. C. (2013) · Nature reviews. Immunology · doi:10.1038/nri3495 · Cited by 1,866 · see citing works

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,841 · see citing works

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,818 · see citing works

Signal Transduction through MAP Kinase Cascades

Lewis, T. S., Shapiro, P. S., & Ahn, N. G. (1998) · Advances in cancer research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,746 · see citing works

AP-1 in cell proliferation and survival

Shaulian, E., & Karin, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204383 · Cited by 1,733 · see citing works

ERK1/2 MAP kinases: Structure, function, and regulation

Roskoski, R. J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,642 · see citing works

Control of cell cycle transcription during G1 and S phases

Bertoli, C., Skotheim, J. M., & de Bruin, R. A. M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3629 · Cited by 1,510 · see citing works

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · see citing works

ERK/MAPK signalling pathway and tumorigenesis (Review)

Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475 · see citing works

Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis

Ouyang, L., Shi, Z., Zhao, S., Wang, F., Zhou, T., Liu, B., & Bao, J. (2012) · Cell Proliferation · doi:10.1111/j.1365-2184.2012.00845.x · Cited by 1,458 · see citing works

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · see citing works

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,397 · see citing works

FAK–Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly

Webb, D. J., Donais, K., Whitmore, L. A., Thomas, S. Μ., Turner, C. E., Parsons, J. T., & Horwitz, A. F. (2004) · Nature Cell Biology · doi:10.1038/ncb1094 · Cited by 1,387 · see citing works

Multiple Ras-dependent phosphorylation pathways regulate Myc protein stabilityPreprint

Sears, R. C., Nuckolls, F., Haura, E. B., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,379 · see citing works

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · see citing works

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346 · see citing works

Protein kinase Cα activates RAF-1 by direct phosphorylation

Kölch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marmé, D., & Rapp, U. R. (1993) · Nature · doi:10.1038/364249a0 · Cited by 1,278 · see citing works

Phosphorylation and Functional Inactivation of TSC2 by Erk

Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268 · see citing works

Raf-1 activates MAP kinase-kinase

Kyriakis, J. M., App, H., Zhang, X., Banerjee, P. T., Brautigan, D. L., Rapp, U. R., & Avruch, J. (1992) · Nature · doi:10.1038/358417a0 · Cited by 1,263 · see citing works

Regulation of Cell Motility by Mitogen-activated Protein Kinase

Klemke, R. L., Cai, S., Giannini, A. L. M., Gallagher, P. J., de Lanerolle, P., & Cheresh, D. A. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.2.481 · Cited by 1,235 · see citing works

The RAF proteins take centre stage

Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,233 · see citing works

Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway

Lavoie, J. N., L’Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,210 · see citing works

BrafV600E cooperates with Pten loss to induce metastatic melanoma

Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189 · see citing works

ERK signalling: A master regulator of cell behaviour, life and fate

Lavoie, H., Gagnon, J., & Therrien, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0255-7 · Cited by 1,185 · see citing works

Targeting RAS–ERK signalling in cancer: promises and challenges

Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163 · see citing works

MAP kinases and cell migration

Huang, C., Jacobson, K., & Schaller, M. D. (2004) · Journal of Cell Science · doi:10.1242/jcs.01481 · Cited by 1,074 · see citing works

Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase

Anderson, N. G., Maller, J. L., Tonks, N. K., & Sturgill, T. W. (1990) · Nature · doi:10.1038/343651a0 · Cited by 1,064 · see citing works

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

Santarpia, L., Lippman, S. M., & El‐Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,033 · see citing works

Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma

Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes &amp; Development · doi:10.1101/gad.1158703 · Cited by 1,033 · see citing works

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V. G., Liszkay, G., Giacomo, A. M. D., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,023 · see citing works

A mechanism of repression of TGFbeta / Smad signaling by oncogenic RasPreprint

Kretzschmar, M., Doody, J. F., Timokhina, I., & Massagué, J. (1999) · Genes & Development · doi:10.1101/gad.13.7.804 · Cited by 997 · see citing works

Mitogen‐ and stress‐activated protein kinase‐1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB

Deák, M., Clifton, A. D., Lucocq, J. M., & Alessi, D. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.15.4426 · Cited by 992 · see citing works

Activation of Raf as a Result of Recruitment to the Plasma Membrane

Stokoe, D., Macdonald, S. G., Cadwallader, K. A., Symons, M. H., & Hancock, J. F. (1994) · Science · doi:10.1126/science.7811320 · Cited by 976 · see citing works

Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter

Gille, H., Sharrocks, A. D., & Shaw, P. E. (1992) · Nature · doi:10.1038/358414a0 · Cited by 966 · see citing works

Ras in Cancer and Developmental Diseases

Fernández‐Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 959 · see citing works

Linking actin dynamics and gene transcription to drive cellular motile functions

Olson, E. N., & Nordheim, A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2890 · Cited by 958 · see citing works

Molecular interpretation of ERK signal duration by immediate early gene products

Murphy, L. O., Smith, S. W., Chen, R., Fingar, D. C., & Blenis, J. (2002) · Nature Cell Biology · doi:10.1038/ncb822 · Cited by 928 · see citing works

ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect

Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C. A., Aldape, K., Cantley, L. C., & Lu, Z. (2012) · Nature Cell Biology · doi:10.1038/ncb2629 · Cited by 910 · see citing works

Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP

Yeung, K. C., Seitz, T., Li, S.-F., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D., Mischak, H., et al. (1999) · Nature · doi:10.1038/43686 · Cited by 909 · see citing works

Inactivation of glycogen synthase kinase-3 <i>β</i> by phosphorylation: new kinase connections in insulin and growth-factor signalling

Sutherland, C., Leighton, I. A., & Cohen, P. (1993) · Biochemical Journal · doi:10.1042/bj2960015 · Cited by 903 · see citing works

Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1

Kretzschmar, M., Doody, J. F., & Massagué, J. (1997) · Nature · doi:10.1038/39348 · Cited by 878 · see citing works

Activation of the MAP kinase pathway by the protein kinase raf

Howe, L. R., Leevers, S. J., Gómez, N., Nakielny, S., Cohen, P., & Marshall, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90361-f · Cited by 801 · see citing works

Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798 · see citing works

A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells

Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791 · see citing works

Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1

Ben-Sahra, I., Howell, J. J., Asara, J. M., & Manning, B. D. (2013) · Science · doi:10.1126/science.1228792 · Cited by 739 · see citing works

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732 · see citing works

PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress

Vazquez, F., Lim, J.-H., Chim, H., Bhalla, K., Girnun, G., Pierce, K., Clish, C. B., Granter, S. R., Widlund, H. R., Spiegelman, B. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.020 · Cited by 715 · see citing works

Erk2 Phosphorylation of Drp1 Promotes Mitochondrial Fission and MAPK-Driven Tumor Growth

Kashatus, J. A., Nascimento, A., Myers, L. J., Sher, A., Byrne, F. L., Hoehn, K. L., Counter, C. M., & Kashatus, D. F. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.01.002 · Cited by 700 · see citing works

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

Yang, J.-Y., Zong, C. S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J.-Y., Lai, C., Chang, C. J., Huang, W., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1676 · Cited by 698 · see citing works

Regulation of RAF protein kinases in ERK signalling

Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 695 · see citing works

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676 · see citing works

Activation of Mitogen-Activated Protein Kinase Kinase by v-Raf in NIH 3T3 Cells and in Vitro

Dent, P., Haser, W. G., Haystead, T., Vincent, L. A., Roberts, T. M., & Sturgill, T. W. (1992) · Science · doi:10.1126/science.1326789 · Cited by 668 · see citing works

Regulation of Raf-1 by direct feedback phosphorylation.

Dougherty, M., Müller, J., Ritt, D. A., Zhou, M., Zhou, X.-Z., Copeland, T., Conrads, T., Veenstra, T., Lu, K., & Morrison, D. (2005) · Molecules and Cells · doi:10.1016/j.molcel.2004.11.055 · Cited by 663 · see citing works

Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1

Kim, J.-W., Gao, P., Liu, Y.-C., Semenza, G. L., & Dang, C. V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00440-07 · Cited by 658 · see citing works

Defective Thymocyte Maturation in p44 MAP Kinase (Erk 1) Knockout Mice

Pagès, G., Guérin, S., Grall, D., Bonino, F., Smith, A., Anjuere, F., Auberger, P., & Pouysségur, J. (1999) · Science · doi:10.1126/science.286.5443.1374 · Cited by 654 · see citing works

Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

Shi, H., Moriceau, G., Kong, X., Lee, M., Lee, H., Koya, R. C., Ng, C., Chodon, T., Scolyer, R. A., Dahlman, K. B., et al. (2012) · Nature Communications · doi:10.1038/ncomms1727 · Cited by 637 · see citing works

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

Ohren, J. F., Chen, H., Pavlovsky, A. G., Whitehead, C. E., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C. A., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 635 · see citing works

MEK1 mutations confer resistance to MEK and B-RAF inhibition

Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633 · see citing works

MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes

Hemesath, T. J., Price, E. R., Takemoto, C. M., Badalian, T. M., & Fisher, D. E. (1998) · Nature · doi:10.1038/34681 · Cited by 631 · see citing works

STAT3 Serine Phosphorylation by ERK-Dependent and -Independent Pathways Negatively Modulates Its Tyrosine Phosphorylation

Chung, J., Uchida, E., Grammer, T. C., & Blenis, J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6508 · Cited by 620 · see citing works

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · see citing works

PGC1α and mitochondrial metabolism – emerging concepts and relevance in ageing and neurodegenerative disorders

Austin, S., & St‐Pierre, J. (2012) · Journal of Cell Science · doi:10.1242/jcs.113662 · Cited by 606 · see citing works

From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

Yeh, S., Lin, H., Kang, H., Thin, T. H., Lin, M., & Chang, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5458 · Cited by 594 · see citing works

Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 adipocytes that phosphorylates microtubule-associated protein 2 in vitro.

Ray, L. B., & Sturgill, T. W. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.6.1502 · Cited by 592 · see citing works

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., Rominger, C. M., Erskine, S. G., Fisher, K. E., Yang, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2200 · Cited by 591 · see citing works

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D. J., Brandhuber, B. J., Gross, S. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 583 · see citing works

Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases

Gomez, N. M., & Cohen, P. (1991) · Nature · doi:10.1038/353170a0 · Cited by 580 · see citing works

Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6.

Nakajima, T., Kinoshita, S. M., Sasagawa, T., Sasaki, K., Naruto, M., Kishimoto, T., & Akira, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2207 · Cited by 578 · see citing works

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562 · see citing works

Activation of ternary complex factor Elk‐1 by MAP kinases.

Janknecht, R., Ernst, W. H., Pingoud, V., & Nordheim, A. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06204.x · Cited by 561 · see citing works

Regulating the regulator: post-translational modification of RAS

Ahearn, I. M., Haigis, K. M., Bar‐Sagi, D., & Philips, M. R. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3255 · Cited by 560 · see citing works

MYC: Connecting selective transcriptional control to global RNA production

Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521 · see citing works

PKM2, cancer metabolism, and the road ahead

Dayton, T. L., Jacks, T., & Vander Heiden, M. G. (2016) · The EMBO Reports · doi:10.15252/embr.201643300 · Cited by 515 · see citing works

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

Montagut, C. O., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M. J., Ulkus, L. E., Dias-Santagata, D. C., Stubbs, H., Lee, D. W., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508 · see citing works

Multiple components in an epidermal growth factor-stimulated protein kinase cascade

Ahn, N. G., Seger, R., Bratlien, R. L., Diltz, C. D., Tonks, N. K., & Krebs, E. G. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)64310-1 · Cited by 492 · see citing works

Oncogenic K‐Ras decouples glucose and glutamine metabolism to support cancer cell growth

Gaglio, D., Metallo, C. M., Gameiro, P. A., Hiller, K., Danna, L. S., Balestrieri, C., Alberghina, L., Stephanopoulos, G., & Chiaradonna, F. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.56 · Cited by 492 · see citing works

A new mouse model to explore the initiation, progression, and therapy of BRAF V600E -induced lung tumorsPreprint

Dankort, D. L., Filenova, E., Collado, M., Serrano, M., Jones, K. D., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 476 · see citing works

Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK

Allan, L. A., MORRICE, N. A., Brady, S. C., Magee, G. J., Pathak, S., & Clarke, P. R. (2003) · Nature Cell Biology · doi:10.1038/ncb1005 · Cited by 474 · see citing works

Targeting Alterations in the RAF–MEK Pathway

Yaeger, R. D., & Corcoran, R. B. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1321 · Cited by 474 · see citing works

Phosphorylation of the Cap-Binding Protein Eukaryotic Translation Initiation Factor 4E by Protein Kinase Mnk1 In Vivo

Waskiewicz, A. J., Johnson, J. C., Penn, B. H., Mahalingam, M., Kimball, S. R., & Cooper, J. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1871 · Cited by 469 · see citing works

Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus.

Rapp, U. R., Goldsborough, M. D., Mark, G. E., Bonner, T. I., Groffen, J., Reynolds, F. H., & Stephenson, J. R. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4218 · Cited by 467 · see citing works

TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways

Štefanová, I., Hemmer, B., Vergelli, M., Martin, R., Biddison, W. E., & Germain, R. N. (2003) · Nature Immunology · doi:10.1038/ni895 · Cited by 465 · see citing works

Ras oncogenes and their downstream targets

Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, Š. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.012 · Cited by 458 · see citing works

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455 · see citing works

Spred is a Sprouty-related suppressor of Ras signalling

Wakioka, T., Sasaki, A. T., Kato, R., Shouda, T., Matsumoto, A., Miyoshi, K., Tsuneoka, M., Komiya, S., Baron, R., & Yoshimura, A. (2001) · Nature · doi:10.1038/35088082 · Cited by 446 · see citing works

The gene expression signatures of melanoma progression

Haqq, C. M., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D. B., Pulliam, B. L., Federman, S., Miller, J. R., Allen, R. E., Singer, M. I., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501564102 · Cited by 437 · see citing works

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Sullivan, R. J., Infante, J. R., Jankú, F., Wong, D. J. L., Sosman, J. A., Keedy, V. L., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 436 · see citing works

Ets-related protein Elk-1 is homologous to the c-fos regulatory factor p62TCF

Hipskind, R. A., Roa, V. N., Muller, C. G. F., Raddy, E. S. P., & Nordheim, A. (1991) · Nature · doi:10.1038/354531a0 · Cited by 430 · see citing works

Therapeutic strategies to target RAS-mutant cancers

Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420 · see citing works

Reduced MAP Kinase Phosphatase-1 Degradation After p42/p44 MAPK -Dependent Phosphorylation

Brondello, J., Pouysségur, J., & McKenzie, F. R. (1999) · Science · doi:10.1126/science.286.5449.2514 · Cited by 419 · see citing works

Balancing BMP Signaling through Integrated Inputs into the Smad1 Linker

Sapkota, G. P., Alarcón, C. R., Spagnoli, F. M., Brivanlou, A. H., & Massagué, J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.006 · Cited by 419 · see citing works

Regulation and Role of Raf-1/B-Raf Heterodimerization

Rushworth, L. K., Hindley, A. D., O’Neill, E. E., & Kölch, W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2262-2272.2006 · Cited by 419 · see citing works

Binding of 14-3-3 Proteins to the Protein Kinase Raf and Effects on Its Activation

Freed, E., Symons, M. H., Macdonald, S. G., McCormick, F. P., & Ruggieri, R. (1994) · Science · doi:10.1126/science.8085158 · Cited by 414 · see citing works

Mechanisms of regulating the Raf kinase family

Kopera, H. C., Vikis, H. G., & Guan, K. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00139-0 · Cited by 407 · see citing works

New perspectives for targeting RAF kinase in human cancer

Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404 · see citing works

Insulin-stimulated microtubule-associated protein kinase is phosphorylated on tyrosine and threonine in vivo.

Ray, L. B., & Sturgill, T. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.3753 · Cited by 398 · see citing works

On being the right (cell) size

Ginzberg, M., Kafri, R., & Kirschner, M. (2015) · Science · doi:10.1126/science.1245075 · Cited by 390 · see citing works

Mechanism of Suppression of the Raf/MEK/Extracellular Signal-Regulated Kinase Pathway by the Raf Kinase Inhibitor Protein

Yeung, K. C., Janosch, P., McFerran, B. W., Rose, D. W., Mischak, H., Sedivy, J. M., & Kölch, W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3079-3085.2000 · Cited by 389 · see citing works

Mitochondrial Division Is Requisite to RAS-Induced Transformation and Targeted by Oncogenic MAPK Pathway Inhibitors

Serasinghe, M. N., Wieder, S. Y., Renault, T. T., Elkholi, R., Asciolla, J. J., Yao, J. L., Jabado, O., Hoehn, K. L., Kageyama, Y., Sesaki, H., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.01.003 · Cited by 388 · see citing works

RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

Oberholzer, P. A., Kee, D., Dziunycz, P., Sucker, A., Kamsu-Kom, N., Jones, R. T., Roden, C., Chalk, C. J., Ardlie, K., Palescandolo, E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7680 · Cited by 386 · see citing works

Inhibition of Ras for Cancer Treatment: The Search Continues

Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 384 · see citing works

A model for RAS mutation patterns in cancers: finding the sweet spot

Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384 · see citing works

RAF inhibitors that evade paradoxical MAPK pathway activation

Zhang, C., Spevak, W. R., Zhang, Y., Burton, E. A., Ma, Y., Habets, G. G. M., Zhang, J., Lin, J. Y.-S., Ewing, T. J. A., Matusow, B., et al. (2015) · Nature · doi:10.1038/nature14982 · Cited by 382 · see citing works

Sequential Phosphorylation by Mitogen-activated Protein Kinase and Glycogen Synthase Kinase 3 Represses Transcriptional Activation by Heat Shock Factor-1

Chu, B., Soncin, F., Price, B. D., Stevenson, M. A., & Calderwood, S. K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30847 · Cited by 382 · see citing works

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377 · see citing works

RAF protein-serine/threonine kinases: Structure and regulation

Roskoski, R. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 377 · see citing works

Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway.

Blagosklonny, M. V., Schulte, T., Nguyen, P., Trepel, J. B., & Neckers, L. (1996) · PubMed · Cited by 375 · see citing works

Identification of Regulatory Phosphorylation Sites in Mitogen-activated Protein Kinase (MAPK)-activated Protein Kinase-1a/p90 That Are Inducible by MAPK

Dalby, K. N., MORRICE, N. A., Caudwell, F. B., Avruch, J., & Cohen, P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1496 · Cited by 373 · see citing works

Four Key Steps Control Glycolytic Flux in Mammalian Cells

Tanner, L. B., Goglia, A. G., Wei, M. H., Sehgal, T., Parsons, L. R., Park, J. O., White, E., Toettcher, J. E., & Rabinowitz, J. D. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.003 · Cited by 368 · see citing works

Phosphorylation of the Human MicroRNA-Generating Complex Mediates MAPK/Erk Signaling

Paroo, Z., Ye, X., Chen, S., & Liu, Q. (2009) · Cell · doi:10.1016/j.cell.2009.06.044 · Cited by 366 · see citing works

An essential function of the mitogen‐activated protein kinase Erk2 in mouse trophoblast development

Saba‐El‐Leil, M. K., Vella, F. D. J., Vernay, B., Voisin, L., Chen, L., Labrecque, N., Ang, S., & Meloche, S. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor939 · Cited by 366 · see citing works

Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis

Fu, Z., Smith, P. C., Zhang, L., Rubin, M. A., Dunn, R. L., Yao, Z., & Keller, E. T. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.878 · Cited by 365 · see citing works

Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases

Bennett, A. M., & Tonks, N. K. (1997) · Science · doi:10.1126/science.278.5341.1288 · Cited by 359 · see citing works

Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation

Zheng, B., Jeong, J. H., Asara, J. M., Yuan, Y.-Y., Granter, S. R., Chin, L., & Cantley, L. C. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.026 · Cited by 359 · see citing works

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Ross, J. S., Wang, K., Chmielecki, J., Gay, L. M., Johnson, A., Chudnovsky, J., Yelensky, R., Lipson, D., Ali, S. M., Elvin, J. A., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29825 · Cited by 354 · see citing works

<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350 · see citing works

Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase.

Fabian, J. R., Daar, I. O., & Morrison, D. K. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.11.7170 · Cited by 349 · see citing works

Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival

Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347 · see citing works

Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta

Giroux, S., Tremblay, M. G., Bernard, D., Cardin-Girard, J.-F., Aubry, S., Larouche, L., Rousseau, S., Huot, J. L., Landry, J., Jeannotte, L., et al. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80164-x · Cited by 342 · see citing works

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

Welsh, S. J., & Corrie, P. G. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014566428 · Cited by 341 · see citing works

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

Allen, J. E., Krigsfeld, G. S., Mayes, P. A., Patel, L., Dicker, D. T., Patel, A. S., Dolloff, N. G., Messaris, E. G., Scata, K. A., Wang, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004828 · Cited by 341 · see citing works

Active ERK/MAP kinase is targeted to newly forming cell–matrix adhesions by integrin engagement and v‐Src

Fincham, V. J., James, M., Frame, M. C., & Winder, S. J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2911 · Cited by 340 · see citing works

KSR, a novel protein kinase required for RAS signal transduction

Therrien, M., Chang, H. C., Solomon, N. M., Karim, F. D., Wassarman, D. A., & Rubin, G. M. (1995) · Cell · doi:10.1016/0092-8674(95)90204-x · Cited by 340 · see citing works

Receptor Tyrosine Kinases: Legacy of the First Two DecadesPreprint

Schlessinger, J. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008912 · Cited by 339 · see citing works

A Network of Immediate Early Gene Products Propagates Subtle Differences in Mitogen-Activated Protein Kinase Signal Amplitude and Duration

Murphy, L. O., MacKeigan, J. P., & Blenis, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.144-153.2004 · Cited by 332 · see citing works

Identification of the major phosphorylation sites of the Raf-1 kinase

Morrison, D. K., Heidecker, G., Rapp, U. R., & Copeland, T. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85336-x · Cited by 328 · see citing works

Comparative Metabolic Flux Profiling of Melanoma Cell Lines

Scott, D. A., Richardson, A. D., Filipp, F. V., Knutzen, C. A., Chiang, G. G., Ronai, Z. A., Osterman, A. L., & Smith, J. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.282046 · Cited by 328 · see citing works

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327 · see citing works

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K. W., Price, S., Heald, R. A., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 323 · see citing works

Raf kinases: Function, regulation and role in human cancer

Leicht, D. T., Balan, V., Kaplun, A., Singh‐Gupta, V., Kaplun, L., Dobson, M., & Tzivion, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.001 · Cited by 320 · see citing works

Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes

Park, E., Rawson, S. D., Li, K., Kim, B.-W., Ficarro, S. B., Pino, G. L. G., Sharif, H., Marto, J. A., Jeon, H., & Eck, M. J. (2019) · Nature · doi:10.1038/s41586-019-1660-y · Cited by 314 · see citing works

Active Ras induces heterodimerization of cRaf and BRaf.

Weber, C., Slupsky, J. R., Kalmes, H. A., & Rapp, U. R. (2001) · PubMed · Cited by 312 · see citing works

Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene

Mikula, M., Schreiber, M., Husak, Z., Kučerová, L., Rüth, J., Wieser, R., Zatloukal, K., Beug, H., Wagner, E. F., & Baccarini, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1952 · Cited by 311 · see citing works

MEK kinase activity is not necessary for Raf‐1 function

Hüser, M., Luckett, J., Chiloeches, A., Mercer, K., Iwobi, M., Giblett, S., Sun, X., Brown, J., Marais, R., & Pritchard, C. A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1940 · Cited by 310 · see citing works

Self-renewal of embryonic stem cells by a small molecule

Chen, S., Tae, J., Zhang, Q., Yao, S., Yan, F., Peters, E. C., Schöler, H. R., Schultz, P. G., & Ding, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608156103 · Cited by 310 · see citing works

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B. M., Egyházi, S., Hansson, J., Wu, H., King, A. J., Belle, P. A. V., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 310 · see citing works

The C. elegans ksr-1 gene encodes a novel raf-related kinase involved in Ras-mediated signal transduction

Sundaram, M. V., & Han, M. (1995) · Cell · doi:10.1016/0092-8674(95)90205-8 · Cited by 308 · see citing works

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities

Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C., & Martins, C. P. (2016) · Nature · doi:10.1038/nature16967 · Cited by 308 · see citing works

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.045 · Cited by 304 · see citing works

Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation.

Clarke, M. F., Kukowska‐Latallo, J. F., Westin, E. H., Smith, M. J., & Prochownik, E. V. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.884 · Cited by 299 · see citing works

Endothelial apoptosis in Braf-deficient mice

Wojnowski, L., Zimmer, A. M., Beck, T. W., Hahn, H., Bernal, R. A., Rapp, U. R., & Zimmer, A. (1997) · Nature Genetics · doi:10.1038/ng0797-293 · Cited by 299 · see citing works

The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans

Kornfeld, K., Hom, D. B., & Horvitz, H. R. (1995) · Cell · doi:10.1016/0092-8674(95)90206-6 · Cited by 299 · see citing works

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 298 · see citing works

Essential role for ERK2 mitogen‐activated protein kinase in placental development

Hatano, N., Mori, Y., Oh‐hora, M., Kosugi, A., Fujikawa, T., Nakai, N., Niwa, H., Miyazaki, J., Hamaoka, T., & Ogata, M. (2003) · Genes to Cells · doi:10.1046/j.1365-2443.2003.00680.x · Cited by 296 · see citing works

Rsk1 mediates a MEK–MAP kinase cell survival signal

Shimamura, A., Ballif, B. A., Richards, S. A., & Blenis, J. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00310-9 · Cited by 296 · see citing works

Role of mitogen-activated protein kinase kinase kinases in signal integration

Cuevas, B. D., Abell, A. N., & Johnson, G. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210409 · Cited by 294 · see citing works

ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation

Habelhah, H., Shah, K., Huang, L., Ostareck‐Lederer, A., Burlingame, A. L., Shokat, K. M., Hentze, M. W., & Ronai, Z. A. (2001) · Nature Cell Biology · doi:10.1038/35060131 · Cited by 292 · see citing works

Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factorPreprint

Niu, H., Ye, B. H., & Dalla‐Favera, R. (1998) · Genes & Development · doi:10.1101/gad.12.13.1953 · Cited by 292 · see citing works

Erk/Src Phosphorylation of Cortactin Acts as a Switch On-Switch Off Mechanism That Controls Its Ability To Activate N-WASP

Martı́nez-Quiles, N., Ho, H. H., Kirschner, M. W., Ramesh, N., & Geha, R. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5269-5280.2004 · Cited by 292 · see citing works

Current Development Status of MEK Inhibitors

Cheng, Y., & Tian, H. (2017) · Molecules · doi:10.3390/molecules22101551 · Cited by 291 · see citing works

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901

Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., LePage, S., Leopold, W. R., et al. (2008) · Bioorganic &amp; Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.054 · Cited by 289 · see citing works

Identification of Two Sp1 Phosphorylation Sites for p42/p44 Mitogen-activated Protein Kinases

Milanini, J., Pouysségur, J., & Pagès, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201753200 · Cited by 288 · see citing works

Identification of the First Specific Inhibitor of p90 Ribosomal S6 Kinase (RSK) Reveals an Unexpected Role for RSK in Cancer Cell Proliferation

Smith, J. A., Poteet-Smith, C. E., Xu, Y.-M., Errington, T. M., Hecht, S. M., & Lannigan, D. A. (2005) · Cancer Research · doi:10.1158/0008-5472.1027.65.3 · Cited by 287 · see citing works

Erk1/2-dependent Phosphorylation of Gα-interacting Protein Stimulates Its GTPase Accelerating Activity and Autophagy in Human Colon Cancer Cells

Ogier‐Denis, É., Pattingre, S., Benna, J. E., & Codogno, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006198200 · Cited by 287 · see citing works

A reinvestigation of the multisite phosphorylation of the transcription factor c‐Jun

Morton, S., Davis, R. J., McLaren, A., & Cohen, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg388 · Cited by 281 · see citing works

Response of BRAF -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Parmenter, T. J., Kleinschmidt, M., Kinross, K. M., Bond, S. T., Li, J., Kaadige, M. R., Rao, A. D., Sheppard, K. E., Hugo, W., Pupo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0440 · Cited by 281 · see citing works

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling

Divakar, S. K. A., Carpio, R. V., Dutta, K., Baker, S. J., Cosenza, S. C., Basu, I., Gupta, Y. K., Reddy, M. V. R., Ueno, L. A., Hart, J. R., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.045 · Cited by 278 · see citing works

MEK1/2 dual-specificity protein kinases: Structure and regulation

Roskoski, R. J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.145 · Cited by 277 · see citing works

PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation

Slack‐Davis, J. K., Eblen, S. T., Zečević, M., Boerner, S. A., Tarcsafalvi, A., Diaz, H. B., Marshall, M. S., Weber, M. J., Parsons, J. T., & Catling, A. D. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200212141 · Cited by 277 · see citing works

Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming

Prieto, J., León, M., Ponsoda, X., Sendra, R., Bort, R., Ferrer‐Lorente, R., Raya, Á., López‐García, C., & Torres, J. (2016) · Nature Communications · doi:10.1038/ncomms11124 · Cited by 275 · see citing works

Comparative analysis of the ternary complex factors Elk‐1, SAP‐1a and SAP‐2 (ERP/NET).

Price, M. A., Rogers, A. F., & Treisman, R. (1995) · EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07257.x · Cited by 274 · see citing works

Functional Specificity of Ras Isoforms: So Similar but So Different

Castellano, E., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911408081 · Cited by 273 · see citing works

Epidermal Growth Factor Activates m-Calpain (Calpain II), at Least in Part, by Extracellular Signal-Regulated Kinase-Mediated Phosphorylation

Glading, A., Bodnar, R. J., Reynolds, I. J., Shiraha, H., Satish, L., Potter, D. A., Blair, H. C., & Wells, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.6.2499-2512.2004 · Cited by 271 · see citing works

The MAP kinase ERK2 inhibits the cyclic AMP‐specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579

Hoffmann, R., Baillie, G. S., MacKenzie, S. J., Yarwood, S. J., & Houslay, M. D. (1999) · The EMBO Journal · doi:10.1093/emboj/18.4.893 · Cited by 270 · see citing works

Kinase Suppressor of Ras (KSR) Is a Scaffold Which Facilitates Mitogen-Activated Protein Kinase Activation In Vivo

Nguyen, A., Burack, R., Stock, J. L., Kortum, R. L., Chaika, O. V., Afkarian, M., Muller, W. J., MURPHY, K. M. M., Morrison, D. K., Lewis, R. E., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.9.3035-3045.2002 · Cited by 269 · see citing works

ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)

Carriere, A., Romeo, Y., Acosta-Jaquez, H. A., Moreau, J., Bonneil, E., Thibault, P., Fingar, D. C., & Roux, P. P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.159046 · Cited by 268 · see citing works

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

Fransén, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh049 · Cited by 268 · see citing works

Identification of MAPK Phosphorylation Sites and Their Role in the Localization and Activity of Hypoxia-inducible Factor-1α

Mylonis, I., Chachami, G., Samiotaki, M. K., Panayotou, G., Paraskeva, E., Kalousi, A., Georgatsou, E., Bonanou, S., & Simos, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605058200 · Cited by 266 · see citing works

Paradoxical activation of Raf by a novel Raf inhibitor

Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Boyle, F. T., Hewitt, N., Plant, H., & Hedge, P. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80088-x · Cited by 266 · see citing works

ERK-Dependent Phosphorylation of the Transcription Initiation Factor TIF-IA Is Required for RNA Polymerase I Transcription and Cell Growth

Zhao, J., Yuan, X., Frödin, M., & Grummt, I. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00036-4 · Cited by 259 · see citing works

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesisPreprint

Vredeveld, L. C. W., Possik, P. A., Smit, M. A., Meissl, K., Michaloglou, C., Horlings, H. M., Ajouaou, A., Kortman, P. C., Dankort, D. L., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.187252.112 · Cited by 258 · see citing works

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

Rheault, T., Stellwagen, J. C., Adjabeng, G. M., Hornberger, K. R., Petrov, K. G., Waterson, A. G., Dickerson, S. H., Mook, R. A., Laquerre, S. G., King, A. J., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000063 · Cited by 257 · see citing works

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis

Santana-Codina, N., Roeth, A. A., Zhang, Y., Yang, A., Mashadova, O., Asara, J. M., Wang, X., Bronson, R. T., Lyssiotis, C. A., Ying, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07472-8 · Cited by 252 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Hepatocellular carcinoma: signaling pathways and therapeutic advances

Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 387 · see citing works

Therapeutic advances of targeting receptor tyrosine kinases in cancer

Tomuleasa, C., Tigu, A.-B., Munteanu, R. A., Moldovan, C. S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 279 · see citing works

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 269 · see citing works

The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer

Guo, Z., Chen, D., Yao, L., Sun, Y., Li, D., Le, J., Dian, Y., Zeng, F., Chen, X., & Deng, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02192-0 · Cited by 201 · see citing works

Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies

He, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01891-4 · Cited by 132 · see citing works

Navigating the ERK1/2 MAPK Cascade

Martín-Vega, A., & Cobb, M. H. (2023) · Biomolecules · doi:10.3390/biom13101555 · Cited by 124 · see citing works

Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy

Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 111 · see citing works

From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress

Dewdney, B., Jenkins, M. R., Best, S. A., Freytag, S., Prasad, K., Holst, J., Endersby, R., & Johns, T. G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01637-8 · Cited by 100 · see citing works

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Larráyoz, M., Garcia-Barchino, M. J., Celay, J., Etxebeste, A., Jiménez, M., Pérez, C., Ordóñez, R., Cobaleda, C., Botta, C., Fresquet, V. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02178-3 · Cited by 90 · see citing works

Targeting oxidative stress-mediated regulated cell death as a vulnerability in cancer

Chen, D., Guo, Z., Yao, L., Sun, Y., Dian, Y., Zhao, D., Ke, Y., Zeng, F., Zhang, C., Deng, G., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103686 · Cited by 88 · see citing works

Natural products targeting the MAPK-signaling pathway in cancer: overview

Shi, A., Liu, L., Li, S., & Qi, B. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05572-7 · Cited by 76 · see citing works

A Comprehensive Review and Androgen Deprivation Therapy and Its Impact on Alzheimer’s Disease Risk in Older Men with Prostate Cancer

Singh, M., Agarwal, V., Pancham, P., Jindal, D., Agarwal, S., Rai, S., Singh, S., & Gupta, V. (2024) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s445130 · Cited by 73 · see citing works

On a sugar high: Role of O-GlcNAcylation in cancer

Minh, G. L., Esquea, E. M., Young, R. G., Huang, J., & Reginato, M. J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105344 · Cited by 71 · see citing works

Combined Analysis of Network Toxicology and Multiomics Revealed the Potential Mechanism of 6PPDQ-Induced Hepatotoxicity in Mice

Li, B., Xu, C., Zhang, D., Wang, S., Xu, J., Xiao, B., Yue, F., Fu, H.-Y., Chen, X., & Zhang, Z. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.5c03906 · Cited by 67 · see citing works

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Váraljai, R., Zimmer, L., Al-Matary, Y. S., Kaptein, P., Albrecht, L. J., Shannan, B., Brase, J. C., Gusenleitner, D., Amaral, T. M. S., Wyss, N., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00610-2 · Cited by 67 · see citing works

Analysis of environmental pollutant Bisphenol F elicited prostate injury targets and underlying mechanisms through network toxicology, molecular docking, and multi-level bioinformatics data integration

Huang, S. (2024) · Toxicology · doi:10.1016/j.tox.2024.153847 · Cited by 66 · see citing works

Oxytocin alleviates cognitive and memory impairments by decreasing hippocampal microglial activation and synaptic defects via OXTR/ERK/STAT3 pathway in a mouse model of sepsis-associated encephalopathy

Jiang, J., Zou, Y., Xie, C., Yang, M., Tong, Q., Yuan, M.-M., Pei, X., Deng, S., Tian, M., Xiao, L., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.08.023 · Cited by 59 · see citing works

The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies

İmani, S., Roozitalab, G., Emadi, M., Moradi, A., Behzadi, P., & Kaboli, P. J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1504142 · Cited by 62 · see citing works

ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

Timofeev, O. N., Giron, P., Lawo, S., Pichler, M., & Noeparast, M. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00554-5 · Cited by 59 · see citing works

Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors

Fu, L., Chen, S., He, G., Chen, Y., & Liu, B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01244 · Cited by 53 · see citing works

The Tumor Microenvironment: Signal Transduction

Zhang, X., Ma, H., Gao, Y., Liang, Y., Du, Y., Hao, S., & Ni, T. (2024) · Biomolecules · doi:10.3390/biom14040438 · Cited by 55 · see citing works

MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB

Wang, X., Xiao, T., Chen, P., Jiang, P., Li, W., Chang, H., Wei, C., Lai, X., Zhang, H., Pan, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01986-y · Cited by 48 · see citing works

SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC

Élez, E., Kopetz, S., Tabernero, J. M., Bekaii‐Saab, T., Taı̈eb, J., Yoshino, T., Manji, G. A., Fernandez, K. C., Abbattista, A., Zhang, X., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-1249 · Cited by 47 · see citing works

Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies

Yang, J., Zhou, F., Luo, X., Fang, Y., Wang, X., Liu, X., Xiao, R., Jiang, D., Tang, Y., Yang, G., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02366-3 · Cited by 50 · see citing works

PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer

Wu, L., Huang, S., Tian, W., Liu, P., Xie, Y., Qiu, Y., Li, X., Tang, Y., Zheng, S., Sun, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01771-w · Cited by 44 · see citing works

The Multifaceted Role of miR-21 in Pancreatic Cancers

Chen, C., Demirkhanyan, L. H., & Gondi, C. S. (2024) · Cells · doi:10.3390/cells13110948 · Cited by 44 · see citing works

Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies

Wu, W., Xue, X., Chen, Y., Zheng, N., & Wang, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106456 · Cited by 43 · see citing works

PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway

Li, N., Zuo, R., He, Y., Gong, W., Wang, Y., Chen, L.-W., Luo, Y., Zhang, C., Liu, Z., Chen, P., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06945-7 · Cited by 43 · see citing works

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies

Noeraparast, M., Krajina, K., Pichler, R., Niedersüß-Beke, D., Shariat, S., Grünwald, V., Ahyai, S., & Pichler, M. (2024) · Cancer Communications · doi:10.1002/cac2.12602 · Cited by 45 · see citing works

Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway

Zhao, J., & Luo, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095158 · Cited by 42 · see citing works

Role of ENO1 and its targeted therapy in tumors

Li, Y., Liu, L., & Li, B. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05847-8 · Cited by 42 · see citing works

The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas—New Potential Therapeutic Approach—A Systematic Review

Derwich-Rudowicz, A., Sykutera, M., Bromińska, B., Rubiś, B., Ruchała, M., & Sawicka‐Gutaj, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310952 · Cited by 40 · see citing works

A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression

Liu, W., Ding, Z., Tao, Y., Liu, S., Jiang, M., Yi, F., Wang, Z., Han, Y., Zong, H., Li, D., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02051-6 · Cited by 37 · see citing works

Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling

Zhang, H., He, F., Gao, G., Sheng, L., Wei, Q., Hu, H., Wu, Z., Fang, M., & Wang, X. (2023) · Molecules · doi:10.3390/molecules28030943 · Cited by 33 · see citing works

Withanolides: Promising candidates for cancer therapy

Zhang, Q., Yuan, Y., Cao, S., Kang, N., & Qiu, F. (2024) · Phytotherapy Research · doi:10.1002/ptr.8090 · Cited by 33 · see citing works

Oxidative stress in endometriosis: Sources, mechanisms and therapeutic potential of antioxidants (Review)

Huang, L., Shi, L., Li, M., Yin, X., & Ji, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5513 · Cited by 41 · see citing works

Molecular changes driving low-grade serous ovarian cancer and implications for treatment

Kelliher, L., Yoeli‐Bik, R., Schweizer, L., & Lengyel, E. R. (2024) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2024-005305 · Cited by 31 · see citing works

Neurobiology of cancer: Adrenergic signaling and drug repurposing

Dong, Z.-K., Wang, Y., Li, W., & Jin, W. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108750 · Cited by 33 · see citing works

The role of acetylation and deacetylation in cancer metabolism

Wang, C., & Ma, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70145 · Cited by 31 · see citing works

Ras isoform-specific expression, chromatin accessibility, and signaling

Nussinov, R., Zhang, M., Maloney, R., & Jang, H. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00817-6 · Cited by 28 · see citing works

LncRNA LINC02253 activates KRT18/MAPK/ERK pathway by mediating N6-methyladenosine modification of KRT18 mRNA in gastric cancer

Gao, Z., Long, Y., Wu, Y., Pu, Y., & Xue, F. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac018 · Cited by 28 · see citing works

Reversible covalent c-Jun N-terminal kinase inhibitors targeting a specific cysteine by precision-guided Michael-acceptor warheads

Bálint, D., Póti, Á. L., Alexa, A., Sok, P., Albert, K., Torda, L., Földesi-Nagy, D., Csókás, D., Turczel, G., Imre, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52573-2 · Cited by 28 · see citing works

Mitochondrial Reactive Oxygen Species (mROS) Generation and Cancer: Emerging Nanoparticle Therapeutic Approaches

Wang, X., & Xiong, X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s510972 · Cited by 27 · see citing works

Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma

Zhang, J., Joshua, A. M., Li, Y., O’Meara, C. H., Morris, M. J., & Khachigian, L. M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216633 · Cited by 27 · see citing works

o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis

Xu, H., Zhao, Q., Cai, D., Chen, X., Zhou, X., Gao, Y., Wu, J., Yuan, S., Li, D., Zhang, R., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03365-z · Cited by 26 · see citing works

Pancreatic Cancer: Pathogenesis and Clinical Studies

Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025) · MedComm · doi:10.1002/mco2.70162 · Cited by 26 · see citing works

Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways

Postwala, H., Shah, Y., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02201-8 · Cited by 26 · see citing works

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 24 · see citing works

Natural epidithiodiketopiperazine alkaloids as potential anticancer agents: Recent mechanisms of action, structural modification, and synthetic strategies

Wang, L., Jiang, Q., Chen, S., Wang, S., Lu, J., Gao, X., Zhang, D., & Jin, X. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106642 · Cited by 25 · see citing works

DUSP2 affects bladder cancer prognosis by down-regulating MEK/ERK and P38 MAPK signaling pathways through PTPN7

Zou, F., Rao, T., Wu, C., Song, T., Li, T., Hu, W., Li, L., Yu, W., & Fan, C. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110893 · Cited by 24 · see citing works

TPI1 promotes MAPK / ERK ‐induced EMT , cell migration and invasion in lung adenocarcinoma

Li, Y., Pan, B., Zhang, F., Jia, X., Zhu, X., Tong, X., Zhao, J., & Li, C. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15196 · Cited by 24 · see citing works

Global scientific trends on thyroid disease in early 21st century: a bibliometric and visualized analysis

Song, M., Sun, W., Liu, Q., Wang, Z., & Zhang, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1306232 · Cited by 24 · see citing works

Gastric Cancer Signaling Pathways and Therapeutic Applications

Wu, M., Yuan, S., Liu, K., Wang, C., & Wen, F. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241271935 · Cited by 24 · see citing works

Microneedles-mediated drug delivery system for the diagnosis and treatment of melanoma

Liu, C., Zhao, Z., Lv, H., Yu, J., & Zhang, P. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112818 · Cited by 24 · see citing works

Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling

Gutierrez, N. M. C., Pujol‐Solé, N., Arifi, Q., Coll, J., Clainche, T. L., & Broekgaarden, M. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10064-0 · Cited by 24 · see citing works

TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling

Xia, K., Zheng, D., Wei, Z., Liu, W., & Guo, W. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06048-9 · Cited by 24 · see citing works

Efficacy of Butyrate to Inhibit Colonic Cancer Cell Growth Is Cell Type-Specific and Apoptosis-Dependent

Oncel, S., Safratowich, B. D., Lindlauf, J. E., Liu, Z., Palmer, D. G., Briske‐Anderson, M., & Zeng, H. (2024) · Nutrients · doi:10.3390/nu16040529 · Cited by 24 · see citing works

GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors

Shilyansky, J. S., Chan, C. J., Xiao, S., Gribovskaja‐Rupp, I., Quelle, D. E., Howe, J. R., Dillon, J. S., & Ear, P. H. (2024) · Surgery · doi:10.1016/j.surg.2024.09.052 · Cited by 23 · see citing works

Natural products modulating MAPK for CRC treatment: a promising strategy

Zhou, L., Zhang, J., Zhao, K., Chen, B., & Sun, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1514486 · Cited by 23 · see citing works

Mutant NPM1-Regulated FTO-Mediated m6A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis

Xiao, Q., Li, L., Ren, J., Peng, M., Jing, Y., Jiang, X., Huang, J., Tao, Y., Lin, C., Yang, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817584 · Cited by 23 · see citing works

GCN5–ERK lactylation–phosphorylation loop amplifies lactate-driven cancer progression

Huang, B., Jin, M., Cui, G., Wang, Z., Wang, F., Chen, M., Zhu, L., Li, Y., Yang, X., Li, R., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-025-02107-8 · Cited by 24 · see citing works

USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway

Li, S., Yang, L., Ding, X., Sun, H., Dong, X., Yang, F., Wang, M., Zhang, H., Li, Y., Li, B., et al. (2024) · Oncogenesis · doi:10.1038/s41389-024-00528-z · Cited by 22 · see citing works

Tumour-agnostic kinase inhibitors

Adashek, J. J., Nikanjam, M., & Kurzrock, R. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01147-y · Cited by 21 · see citing works

The neuroscience of cancer: Focus on neuropeptidergic systems

Dong, Z.-K., Wang, Y., & Jin, W. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.025 · Cited by 22 · see citing works

Development and In Vitro Evaluation of Crizotinib-Loaded Lipid–Polymer Hybrid Nanoparticles Using Box–Behnken Design in Non-small Cell Lung Cancer

Aktas, P. K., Baysal, İ., Ciftci, S. Y., & Arıca, B. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02634-4 · Cited by 21 · see citing works

Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways

Chen, B., Chen, B., Lu, M., Zou, E., Lin, G., Yao, J., Wang, L., Gan, Y., Chen, B., Chen, G., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156022 · Cited by 20 · see citing works

The roles of OGT and its mechanisms in cancer

Liu, X., Wang, J., Xiang, Y., Wang, K., Yan, D., & Tong, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01301-w · Cited by 20 · see citing works

TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas

Liu, Y., Liu, F., Li, C., Zhang, T., Han, T., Dai, Y., Huang, N., Tang, H., Wang, X., Lin, S., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae241 · Cited by 20 · see citing works

Breaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy

Liu, Y., Park, S., & Li, Y. (2025) · Cancers · doi:10.3390/cancers17121941 · Cited by 20 · see citing works

Valtrate, an iridoid compound in Valeriana, elicits anti-glioblastoma activity through inhibition of the PDGFRA/MEK/ERK signaling pathway

Liu, X., Hu, Y., Xue, Z., Zhang, X., Liu, X., Liu, G., Wen, M., Chen, A., Huang, B., Li, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03984-0 · Cited by 20 · see citing works

Predicting the effects of rare genetic variants on oncogenic signaling pathways: A computational analysis of HRAS protein function

Ali, S., Ali, U., Qamar, A., Zafar, I., Yaqoob, M., Ain, Q. U., Rashid, S., Sharma, R., Nafidi, H., Jardan, Y. A. B., et al. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1173624 · Cited by 20 · see citing works

ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21 splicing and stabilizing DDX3X to activate the cRaf-MEK-ERK cascade

Zhang, Q., Zheng, L., Bai, Y., Su, C., Che, Y., Xu, J., Sun, K., Ni, J., Huang, L., Shen, Y., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216426 · Cited by 20 · see citing works

UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway

Zhang, H., Yang, J., Song, Q., Ding, X., Sun, F., & Yang, L. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024014 · Cited by 20 · see citing works

The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling

Yang, Y., Hao, X., Zhang, J., Gao, T., Huo, M., Liu, W., Hu, T., Ma, T., Yuan, B., Zhang, M., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217157 · Cited by 20 · see citing works

Artemisia sieberi Besser essential oil inhibits the growth and migration of breast cancer cells via induction of S-phase arrest, caspase-independent cell death and downregulation of ERK

Break, M. K. B., Hussein, W., Huwaimel, B., Alafnan, A. D., Almansour, K., Alafnan, D., Alshammari, A. S., Alanazi, I. A., Alshammari, D. S., Alanzi, F. S., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116492 · Cited by 19 · see citing works

The m7G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling

Xie, J., Mo, T., Li, R., Zhang, H., Liang, G., Ma, T., Chen, J., Xie, H., Wen, X., Hu, T., et al. (2023) · Cancers · doi:10.3390/cancers15225454 · Cited by 19 · see citing works

Celastrol promotes apoptosis of breast cancer MDA-MB-231 cells by targeting HSDL2

Liu, L., Liu, Y., Zhang, S., Zhang, J., Meng, Y., Liu, D., Gu, L., Zhang, Y., Xu, L., Zhang, Z., et al. (2024) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000102 · Cited by 19 · see citing works

Hydrogen sulfide supplementation as a potential treatment for primary mitochondrial diseases

Slade, L., Deane, C. S., Szewczyk, N. J., Etheridge, T., & Whiteman, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107180 · Cited by 21 · see citing works

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib

Gazzin, A., Fornari, F., Cardaropoli, S., Carli, D., Tartaglia, M., Ferrero, G. B., & Mussa, A. (2024) · Life · doi:10.3390/life14060731 · Cited by 19 · see citing works

Oncogenic mechanisms of COL10A1 in cancer and clinical challenges (Review)

Yi, Q., Zhu, G., Zhu, W., Wang, J., Ouyang, X., Yang, K., & Zhong, J. (2024) · Oncology Reports · doi:10.3892/or.2024.8821 · Cited by 19 · see citing works

Repurposing Anticancer Drugs Targeting the MAPK/ERK Signaling Pathway for the Treatment of Respiratory Virus Infections

Liu, Y., & Luo, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136946 · Cited by 18 · see citing works

Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy

Zou, Z., & Zhong, L. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101403 · Cited by 18 · see citing works

Cancer network pharmacology: multi-network regulatory mechanisms and future directions

Zhao, Z., Le, J., Fu, Z., Yang, S., & Chen, Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02811-4 · Cited by 18 · see citing works

Changes of Signaling Pathways in Hypothalamic Neurons with Aging

Masliukov, P. M. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100523 · Cited by 17 · see citing works

Targeting RAF dimers in RAS mutant tumors: From biology to clinic

Yin, H., Tang, Q., Xia, H., & Bi, F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.018 · Cited by 18 · see citing works

Label-free quantification proteomics analysis reveals acute hyper-osmotic responsive proteins in the gills of Chinese mitten crab (Eriocheir sinensis)

Yang, Z., Zhou, J., Zhu, L., Chen, A., & Cheng, Y. (2022) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2022.101009 · Cited by 17 · see citing works

The cardiac glycoside ZINC253504760 induces parthanatos-type cell death and G2/M arrest via downregulation of MEK1/2 phosphorylation in leukemia cells

Zhou, M., Boulos, J. C., Klauck, S. M., & Efferth, T. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09813-w · Cited by 17 · see citing works

NCOA7 Regulates Growth and Metastasis of Clear Cell Renal Cell Carcinoma via MAPK/ERK Signaling Pathway

Guo, J., Ke, S., Chen, Q., Zhou, J., Guo, J., & Qiu, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411584 · Cited by 17 · see citing works

Ugonin P inhibits lung cancer motility by suppressing DPP-4 expression via promoting the synthesis of miR-130b-5p

Wu, C., Ghule, S. S., Liaw, C., Achudhan, D., Fang, S.-Y., Liu, P., Huang, C., Hsieh, C., & Tang, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115483 · Cited by 17 · see citing works

DHX38 enhances proliferation, metastasis, and EMT progression in NSCLC through the G3BP1-mediated MAPK pathway

Ke, M., Zeng, L., Chen, Y., Ning, J., Zhang, S., Zhao, P., & Yang, S. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110962 · Cited by 17 · see citing works

Oleanolic acid inhibits hypoxic tumor-derived exosomes-induced premetastatic niche formation in hepatocellular carcinoma by targeting ERK1/2-NFκB signaling

Jia, W., Liang, S., Jin, M., Li, S., Yuan, J., Zhang, J., Lin, W., Wang, Y., Nie, S., Ling, C., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155208 · Cited by 17 · see citing works

Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity

You, Q., Li, R., Yao, J., Zhang, Y., Sui, X. Y., Xiao, C., Zhang, J.-B., Xiao, J., Chen, H., Li, H., et al. (2024) · Medical Oncology · doi:10.1007/s12032-023-02295-0 · Cited by 17 · see citing works

SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: A potential therapeutic target

Li, Y., Yang, W., Liu, C., Zhou, S., Liu, X., Zhang, T., Wu, L., Li, X., Zhang, J., & Zhang, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111918 · Cited by 17 · see citing works

Role of N6-methyladenosine in tumor neovascularization

Zhao, L., Li, Q., Zhou, T.-L., Liu, X., Guo, J., Fang, Q., Cao, X., Geng, Q., Yu, Y., Zhang, S., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06931-z · Cited by 17 · see citing works

Effects of histamine on the neuroendocrine-immune regulatory network in the Pacific white shrimp, Litopenaeus vannamei

Lin, C., Yan, P., Lou, Z., Shi, X., Zhao, Q., & Li, E. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.738156 · Cited by 16 · see citing works

TAF15 promotes cell proliferation, migration and invasion of gastric cancer via activation of the RAF1/MEK/ERK signalling pathway

Li, T., Guo, C.-M., Xu, L., Zhang, B., & Huang, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-31959-0 · Cited by 16 · see citing works

mRNA‐Lipid Nanoparticle‐Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple‐Negative Breast Cancer

Li, W., Huang, M., Wu, Z., Zhang, Y., Cai, Y., Su, J., Jia Hui, X. I. A., Yang, F., Xiao, D., Yang, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202309988 · Cited by 16 · see citing works

Application and research progress of cordycepin in the treatment of tumours (Review)

He, R., & Zhou, W. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13285 · Cited by 16 · see citing works

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · see citing works

The biology and oncology of RAF–ERK signaling

Emuss, V., & Marais, R. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50019-7 · Cited by 1 · see citing works

The MEK/ERK Network as a Therapeutic Target in Human Cancer

Barbosa, R. L., Acevedo, L. A., & Marmorstein, R. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0687 · Cited by 212 · see citing works

Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway

Zhao, J., & Luo, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095158 · Cited by 42 · see citing works

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 542 · see citing works